| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 14.04 mm | 14.04 mm | 14.04 mm | 14.04 mm | 14.04 mm | |
| Cash burn (monthly) | 4.57 mm | 2.17 mm | 5.07 mm | 7.84 mm | 2.84 mm | |
| Cash used (since last report) | 12.80 mm | 6.08 mm | 14.21 mm | 21.96 mm | 7.96 mm | |
| Cash remaining | 1.24 mm | 7.96 mm | -166.42 k | -7.92 mm | 6.08 mm | |
| Runway (months of cash) | 0.3 | 3.7 | -0.0 | -1.0 | 2.1 | |
| 13F holders | Current |
|---|---|
| Total holders | 15 |
| Opened positions | 8 |
| Closed positions | 7 |
| Increased positions | 0 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 1.73 bn |
| Total shares | 13.61 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bayer Healthcare | 5.88 mm | $0.00 |
| New Enterprise Associates 15 | 4.43 mm | $0.00 |
| Joe Lonsdale | 2.54 mm | $0.00 |
| NEA Management | 442.62 k | $1.00 bn |
| ARK Investment Management | 176.67 k | $399.27 mm |
| Vanguard | 97.47 k | $220.28 mm |
| Geode Capital Management | 27.29 k | $61.69 mm |
| UBS UBS | 10.50 k | $23.72 mm |
| BlackRock | 4.00 k | $9.05 mm |
| Tower Research Capital | 2.36 k | $5.33 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Dec 24 | Kanya Rajangam | Common Stock Warrant Common Stock | Grant | Acquire A | Yes | No | 2.3 | 49,500 | 113.85 k | 49,500 |
| 9 Dec 24 | Kanya Rajangam | Series A Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 2250 | 33 | 74.25 k | 33 |
| 9 Dec 24 | Fran Schulz | Stock Option Common Stock | Grant | Acquire A | No | No | 6.52 | 12,500 | 81.50 k | 12,500 |
| 9 Dec 24 | Donald F Tang | Stock Option Common Stock | Grant | Acquire A | No | No | 6.52 | 12,500 | 81.50 k | 12,500 |
